MedTrace Logo

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

NCT02583919 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2018-06-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo

Conditions

Interventions

DRUG

ISIS-GCGRRx- Dose Level 1

once weekly dosing for 26 weeks

DRUG

ISIS-GCGRRx- Dose Level 2

once weekly dosing for 26 weeks

DRUG

Placebo

once weekly dosing for 26 weeks

Sponsors & Collaborators

  • Ionis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Sanjay Bhanot · Ionis Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-12-15
Completion
2017-05-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02583919 on ClinicalTrials.gov